Now that Marathon Pharmaceuticals has sold its Duchenne muscular dystrophy drug, the company unceremoniously withdrew from a big industry trade group, which began a review of its membership criteria two months ago after Marathon caused a stink over its pricing.
The drug maker sent a note on Thursday night to the Pharmaceutical Research & Manufacturers of America saying it is “discontinuing its membership in all relevant trade associations” after closing a deal earlier in the day to sell its drug to PTC Therapeutics. This is the second drug maker to leave the trade group. Earlier this month, Mallinckrodt resigned as the trade group proceeded with its review.
The sale of the drug to PTC leaves Marathon without any prescription medicines currently approved for marketing, suggesting the company does not have reason to belong to the trade group. A Marathon spokeswoman declined to comment on the departure, which was first reported by Bloomberg News.
About the Author Reprints
